Overexpression of the HER2/neu oncogene is observed in approximately 30% of human breast carcinoma specimens. HER2/neu overexpression is a negative prognostic factor in breast cancer patients. Cancer cells that overexpress HER2/neu may also be less sensitive to chemotherapy. In order to further de®ne mechanisms by which HER2/neu overexpression drives neoplastic cell growth and chemoresistance, antisense oligonucleotides (ODNs) have been utilized to selectively down-regulate HER2/neu expression in human breast cancer cells. Such antisense ODNs suppress HER2/neu mRNA and protein levels in a dose-dependent, sequence-speci®c manner. Down-regulation of HER2/neu expression in HER2/neu overexpressing breast cancer cells inhibits cell cycle progression in G 0 /G 1 and results in apoptotic cell death. In tissue culture studies, combined treatment of HER2/ neu overexpressing breast cancer cells with HER2/neu antisense ODNs and conventional chemotherapeutic agents results in synergistic inhibition of cancer cell growth and activation of apoptotic cell death mechanisms. These studies have been extended to demonstrate synergistic antitumor eects following systemic treatment with antisense ODNs plus doxorubicin in nude mice bearing human breast carcinoma xenografts. Collectively these ®ndings demonstrate that HER2/neu overexpression stimulates anti-apoptotic cell survival mechanisms and suggest that HER2/neu antisense ODNs may be of use in cancer therapeutics. Oncogene (2000) 19, 6138 ± 6143.
Introduction
Overexpression of the HER2/neu oncogene (also called erbB2), and its protein product, p185 HER2/neu , are seen in approximately 30% of human adenocarcinomas of the breast, as well as in a signi®cant fraction of adenocarcinomas of the lung, ovary and pancreas (Menard et al., 2000) . Overexpression of HER2/neu is a negative prognostic factor following tumor resection (Slamon et al., 1987; Berchuck et al., 1990; Kern et al., 1990) and may be associated with increased resistance to cancer chemotherapy (Baselga et al., 1997; Pegram et al., 1997) . The mechanism(s) by which HER2/neu overexpression stimulates neoplastic cell growth and renders cells chemoresistant have not been completely de®ned. The recent evolution of therapeutic approaches to targeting HER2/neu overexpressing tumors in patients with metastatic breast cancer highlights the importance of further characterizing the role of HER2/ neu overexpression in cancer biology.
We initially demonstrated the direct growth-inhibitory eects of monoclonal antibodies targeting p185 HER2/neu on the surface of HER2/neu transformed cells (Drebin et al., 1984 (Drebin et al., , 1985 (Drebin et al., , 1986 (Drebin et al., , 1988 Katsumata et al., 1995) . Subsequent studies from multiple laboratories have veri®ed these observations and have led to the development of monoclonal antibodies targeting the human HER2/neu product (Hudziak et al., 1989 : Harwirth et al., 1993 : Stancovski et al., 1991 . One such antibody (HERCEPTIN 1 ) has demonstrated signi®cant clinical activity in patients with breast cancer ± particularly when administered in conjunction with conventional chemotherapeutic agents (Baselga et al., 1996; Pegram et al., 1998) .
Numerous other approaches to inhibiting cancer cell growth by down-regulating HER2/neu expression or inhibiting p185 HER2/neu tyrosine kinase activity have shown promise in the laboratory. Several laboratories, including our own, have demonstrated that antisense oligonucleotides (ODNs) can speci®cally down-regulate HER2/neu mRNA expression in cancer cells with resulting inhibitory eects on the proliferation of cancer cells than overexpress HER2/neu (Roh et al., 1999 . Antisense ODNs bind to complementary mRNA sequences through Watson-Crick base pairing, and can activate the degradation of the complementary mRNA by the endogenous nuclease RNAaseH (Green et al., 2000) . Antisense ODNs targeting HER2/neu appear to be more potent than monoclonal antibodies at inhibiting HER2/neu-stimulated neoplastic proliferation in vitro (unpublished results). We have utilized antisense approaches to down-regulate HER2/neu expression in studying the role of HER2/neu overexpression in breast cancer on apoptotic cell death mechanisms and sensitivity to chemotherapeutic agents.
Antisense ODNs specifically inhibit the expression of HER2/neu and inhibit BT474 breast carcinoma cell growth Antisense ODNs can inhibit HER2/neu gene expression in human breast cancer cells, resulting in signi®cant dose-dependent suppression of p185 HER2/neu levels and a resultant inhibition of cancer cell growth (Roh et al., 1998 . The result of a representative experiment, demonstrating antisense suppression of p185 HER2/neu expression, is shown in Figure 1a . Such antisensemediated inhibition of the HER2/neu gene product has no eect on expression of other proteins, including actin (Figure 1a) (Figure 1b) , down-regulation of p185 HER2/neu slightly precedes and generally parallels the biological eects of antisense ODNs in inhibiting the proliferation of BT474 breast carcinoma cells. As p185 HER2/neu levels recover, there is a corresponding recovery of cell proliferation.
The antiproliferative eects of HER2/neu antisense ODNs are sequence-speci®c as well . When BT474 breast carcinoma cells are treated with HER2/neu antisense ODNs, there is a signi®cant inhibition of HER2/neu expression at the mRNA and protein levels, and a corresponding inhibition of cell growth (Figure 2 ). When ODNs mismatched at a single base (out of 15 bases) are substituted for the intact antisense sequence, there is a moderate reduction in activity both in inhibiting HER2/neu expression and in inhibiting BT474 cell growth. A four base mismatched sequence has almost no activity at either inhibiting HER2/neu expression or cancer cell growth. Thus the ability of HER2/neu-speci®c antisense ODNs to inhibit HER2/neu expression, and to interfere with cancer cell growth, are both target-speci®c and sequence-speci®c.
The antiproliferative eects of HER2/neu antisense ODNs appear to be limited to cancer cells that overexpress HER2/neu. As shown in Table 1 , the proliferation of several breast cancer cell lines that overexpress HER2/neu is inhibited by HER2/neu antisense ODN treatment. In contrast, the proliferation of cells with more moderate levels of HER2/neu expression is not signi®cantly altered by HER2/neu antisense ODN treatment. Similar results have been obtained in studies on high and low HER2/neu expressing cancer cells of other histologic types . It is important to note that all of the cell lines, regardless of baseline HER2/neu expression levels, undergo down-regulation of HER2/neu expression in response to HER2/neu antisense ODN treatment (Roh et al., 1998 , data not shown). These results suggest that cancer cells that overexpress HER2/neu require continuous high level expression of p185 HER2/neu . In contrast, cancer cells that express lower levels of HER2/neu have presumably undergone neoplastic transformation by distinct molecular mechanisms, and . Replicate BT474 breast carcinoma cultures were treated with phosphorothioate modi®ed ODNs (1 mM) and Western blots performed on protein lysates after 24 h, as described (Roh et al., 1998) . Lipofectin=10 mg/ml Lipofectin alone; HER2 Antisense=15 base HER2/neu antisense sequence; HER2/neu Scramble=15 base ODN consisting of scrambled antisense sequence nucleotides. (b) Kinetics of p185HER2/neu and cancer cell growth inhibition following HER2/neu antisense ODN treatment. Replicate samples of BT474 cells were treated with HER2/neu antisense ODNs or Lipofectin on day 0. On the days indicated cell lysates were prepared for Western blot analysis and triplicate samples were counted using a hemocytometer. Western blots were quantitated by densitometry. Levels of p185
HER2/neu and cell numbers following antisense treatment are expressed as a percentage of the levels/numbers observed in BT474 cultures treated with Lipofectin alone Figure 2 Sequence speci®city of HER2/neu antisense eects. Replicate BT474 cultures were treated with phosphorothioate ODNs as indicated at 1 mM in the presence of 10 mg/ml Lipofectin for 24 h. Cell lysates were analysed for HER2/neu RNA and protein levels by Northern and Western blotting. Blots were quantitated by densitometry. Cell growth was determined by counting triplicate samples. Results are normalized to levels seen in cells treated with Lipofectin alone. HAS=HER2/neu antisense ODN; 1MM=one base mismatched HER2/neu antisense ODN; 4 MM=four base mismatched HER2/neu antisense ODN; HS=HER2/neu sense sequence ODN; HSC=HER2/neu scrambled sequence ODN. Similar results were presented in Oncogene HER2/neu antisense targeting of breast carcinoma H Roh et al thus are not sensitive to antisense-mediated downregulation of p185 HER2/neu .
Mechanisms of growth inhibition following antisense-mediated down-regulation of HER2/neu expression
The ability of antisense ODNs to speci®cally downregulate HER2/neu expression has been utilized to investigate the mechanisms by which HER2/neu overexpression facilitates neoplastic cell growth. As shown in Figure 3 , down-regulation of p185 HER2/neu using antisense ODNs results in the accumulation of BT474 cells in the G0/G1 phase of the cell cycle. There is a corresponding decrease in cells in the S and G2/M phases of the cell cycle. Similar results are obtained following antisense ODN treatment of the distinct HER2/neu overexpressing breast cancer cell line SKBR3 (Figure 3) . These results suggests that HER2/ neu overexpression in breast cancer cells alters cell cycle regulatory mechanisms controlling G1 progression or the G1/S transition.
In addition to inhibiting cell cycle progression, antisense-mediated down-regulation of HER2/neu expression in HER2/neu overexpressing breast cancer cells results in activation of apoptotic cell death mechanisms . As shown in Figure  4 , antisense treatment of HER2/neu overexpressing BT474 and SKBR3 cells results in activation of CPP32 (caspase 3), a ®nal common eector of apoptotic cell death (Webb et al., 1997) . Treatment with a control scrambled sequence ODN has no such eect on CPP32 activity. There is no eect of HER2/neu antisense ODN treatment on CPP32 activity in the MCF7 breast cancer cell line, which expresses lower levels of HER2/ neu (Figure 4) . Thus HER2/neu overexpression in breast cancer cells appears to act as an anti-apoptotic cell survival factor in cancer cells that overexpress this oncogene.
Synergistic effects of HER2/neu antisense ODNs and conventional chemotherapeutic agents
The ability of HER2/neu overexpression to inhibit apoptotic cell death mechanisms suggests that it might also interfere with the activation of apoptotic cell death in response to treatment with cancer chemotherapeutic agents. Such a mechanism might be responsible for the marked resistance to chemotherapy seen in cancer cells that overexpress HER2/neu (Baselga et al., 1997; Pegram et al., 1997) . In order to test this Figure 3 Eect of HER2/neu down-regulation on cell cycle progression in HER2/neu overexpressing breast cancer cell lines. Cells were treated with ODNs or Lipofectin alone for 24 h and then were pulsed with Bromodeoxyuridine (BrdU) for 30 min. Cells were harvested, ®xed and stained with¯uorescein-labeled anti-BrdU antibody in the presence of propidium iodide. Dual channel cytometry was used to determine cell cycle distribution Figure 4 Down-regulation of HER2/neu expression activates CPP32 in HER2/neu overexpressing breast cancer cells. Cells were treated with ODNs (1 mM) or Lipofectin alone and CPP32 activity was determined as described . Similar results were presented in Roh et al. (2000) (Roh et al., 1999) . As shown in Figure 5 , treatment with either antisense ODNs (0.3 mM) or doxorubicin (0.2 mM) moderately activates CPP32. However, when the two agents are combined there is a greater than additive activation of CPP32, suggesting a synergistic eect on cell death. There is a similar synergistic eect when inhibition of cell proliferation is examined (Roh et al., 1999) . These ®ndings support the possibility that HER2/neu overexpression renders cancer cells resistant to chemotherapeutic agents by altering the balance of cell survival/ cell death signaling.
In vivo synergy of antisense ODNs and doxorubicin in BT474 human breast carcinoma xenografts
Antisense ODNs have entered clinical trials in a variety of human disorders, most prominently cancer (O'Dwyer et al., 1999; Nemunaitis et al., 1999; Waters et al., 2000) . Based on the synergistic activity of HER2/neu antisense ODNs and doxorubicin in inhibiting BT474 cell proliferation and activating apoptotic cell death mechanisms in vitro, we were interested in examining the ability of systemic treatment with HER2/neu antisense ODNs to inhibit the growth of BT474 tumor xenografts in nude mice (Roh et al., 1999) . As shown in Figure 6 , treatment with HER2/neu antisense ODNs results in signi®cant inhibition of BT474 tumor growth; a scrambled sequence control ODN has no such eects. At the doses utilized, doxorubicin has no eect on BT474 tumor growth. Most strikingly, the combination treatment using HER2/neu antisense ODNs and doxorubicin results in enhanced antitumor eects, with complete resolution of tumors in some treated animals (Roh et al., 1999) . Thus HER2/neu antisense ODNs can synergize with conventional chemotherapeutic agents in mediating antitumor eects in vivo.
Discussion
In recent years the HER2/neu oncogene has received a great deal of attention as a potential therapeutic target in breast cancer. HER2/neu is an attractive target for molecular therapeutics both because it is overexpressed in a signi®cant fraction of human tumors, and because its overexpression appears to play a critical role in the biological behavior of the cancer cell. Thus interference with HER2/neu expression or function can inhibit the neoplastic growth of cancer cells. The results of clinical trials using monoclonal antibody approaches to targeting HER2/neu in human breast cancer represent one of the ®rst examples of the successful translation of modern molecular biological research into clinical cancer treatment (Drebin et al., 1984 (Drebin et al., , 1985 (Drebin et al., , 1986 (Drebin et al., , 1988 Katsumata et al., 1995; Hudziak et al., 1989; Stancovski et al., 1991; Baselga et al., 1996; Roh et al., 1998) . However, monoclonal antibodies may not be the ideal mechanism for therapeutic manipulation of HER2/neu signaling pathways. Antibodies only react with cell surface p185HER2/neu; elevated levels of intracellular p185 HER2/neu may deliver mitogenic signals prior to display on the cell membrane (Graus-Porta et al., 1995) . Furthermore, soluble antigenic p185 HER2/neu fragments shed from the tumor cell membrane may interfere with antibody binding to p185 HER2/neu on the tumor cell surface. Such shed tumor antigens have been demonstrated to interfere with the antiproliferative Figure 5 Synergistic activation of CPP32 activity in BT474 cells treated with HER2/neu antisense ODNs and doxorubicin. BT474 cells were treated with ODNs (0.3 mM)+doxorubicin (0.2 mM). CPP32 activity was determined as described . Similar results were presented in Roh et al. (1999) Figure 6 Synergistic inhibition of BT474 xenografts by the combination of HER2/neu antisense ODNs and doxorubicin. Nude mice received BT474 cell implants in the mid-dorsum on day 0. When small tumor nodules were palpable (day 10), mice were randomized into groups of ®ve animals and treated as indicated. Tumor size was measured on day 30 and is expressed as the product of tumor length and width. Results represent means+s.e. of the mean. HBSS=daily injections with Hanks balanced salt solution days 10 ± 23; HER2 Antisense=10 mg/kg daily, days 10 ± 23; HER2 Scramble=10 mg/kg daily, days 10 ± 23; Doxorubicin=10 mg/kg, single dose, day 10; HER2 Antisense+Doxorubicin=antisense ODNs 10 mg/kg, days 10 ± 23 plus doxorubicin 10 mg/kg single dose, day 10. Similar results were presented in Roh et al. (1999) Oncogene HER2/neu antisense targeting of breast carcinoma H Roh et al eects of p185 HER2/neu -speci®c monoclonal antibodies in vitro (Brodowicz et al., 1997) , and the presence of p185 HER2/neu antigenic fragments in patient serum appears to be a predictor of a poor clinical response to p185 HER2/neu monoclonal antibody therapy (Baselga et al., 1996) . Thus the exploration of distinct approaches to targeting HER2/neu in cancer therapy appears warranted.
Antisense oligonucleotides represent a potentially powerful method of selectively inhibiting gene expression (Green et al., 2000; O'Dwyer, 1999; Nemunaitis et al., 1999; Waters et al., 2000) . However, the study of antisense compounds has been plagued by a number of factors resulting in¯awed or incorrect experimental results (Stein, 1995) . ODNs, and particularly the more stable phosphorothioate derivatives used in most experiments, are highly charged molecules that, if utilized at high concentrations (41 mM), may bind to cellular proteins and interfere with biological functions via non-antisense mechanisms (Webb et al., 1997; Stein, 1995) . Furthermore, high concentrations of ODNs may be directly toxic to cells. Again, biological activity attributed to such antisense ODNs may not be the result of the speci®c inhibition of a target gene.
The experimental ®ndings in the HER2/neu antisense studies reviewed here are unlikely to be the result of such non-antisense artifacts. It has been demonstrated that the HER2/neu antisense ODN utilized exerts dosedependent, sequence-speci®c eects on HER2/neu expression. The anticancer eects of the antisense ODN molecule closely parallel eects on gene expression, and occur with a similar time course. Furthermore, experiments have been conducted at ODN concentrations of 1 mM and below to minimize nonspeci®c toxicity and multiple control ODNs have been utilized to con®rm the speci®city of antisense eects. Finally, the selective eects of HER2/neu-speci®c antisense ODNs in inhibiting only the growth of cancer cells that overexpress HER2/neu are quite similar to the results obtained when monoclonal antibodies are utilized to target HER2/neu in such cells (Shepard et al., 1991) . Thus it appears that antisense ODNs represent a distinct and potent mechanism for targeting HER2/neu in breast cancer cells that overexpress this oncogene. A comparison of the activities of HER2/neu-speci®c antisense ODNs and p185HER2/neu-speci®c monoclonal antibodies is presented in Table 2 .
In addition to cytostatic eects, antisense-mediated down-regulation of HER2/neu expression results in the activation of apoptotic cell death mechanisms in cancer cells that overexpress HER2/neu. Exposure to some, but not all, p185 HER2/neu -speci®c monoclonal antibodies also results in apoptotic cell death (Ghetie et al., 1997; Kita et al., 1996) . Thus, cancer cells that overexpress HER2/neu are dependent on p185 HER2/neu for cell survival as well as cell proliferation. The molecular mechanisms by which HER2/neu overexpression alters cell survival/cell death signaling have not been completely de®ned, but the elevated expression of p185 HER2/neu has been linked to two key regulators of apoptotic cell death: Bc12 and Fas ligand (Kumar et al., 1996; Shen and Novak, 1997) .
The cytotoxic eects of most cancer chemotherapeutic agents result from the activation of apoptotic cell death mechanisms following chemotherapy-induced DNA damage. Previous studies have suggested that HER2/neu overexpression facilitates DNA repair mechanisms, and that down-regulation of HER2/neu may reverse these eects (Pietras et al., 1998; You et al., 1998) . It has been demonstrated here that antisense-mediated down-regulation of HER2/neu expression can result in synergistic activation of apoptotic cell death pathways in combination with conventional chemotherapeutic agents. Such synergy might result from eects of HER2/neu down-regulation on DNA repair mechanisms, with resulting increased chemotherapy-mediated toxicity (You et al., 1998) or may re¯ect direct eects of enhancing apoptotic cell death mechanisms resulting from the down-regulation of HER2/neu . It is possible that both of these mechanisms, and possibly additional mechanisms as yet unde®ned, play a role in the synergistic eects of HER2/neu down-regulation and conventional chemotherapeutic agents. The characterization of such mechanisms is an important area for additional study and may lead to further improvements in cancer therapy.
It has been demonstrated here that HER2/neu antisense ODNs, administered systemically, can synergize with doxorubicin in the experimental therapy of human breast carcinoma xenografts in nude mice (Roh et al., 1999) . Current studies in our laboratory are extending these results, investigating distinct antisense compounds and the use of antisense ODNs in conjunction with other chemotherapeutic agents as well as in combination with p185HER2/neu-speci®c monoclonal antibodies. Antisense compounds targeting several distinct oncogenes and growth stimulatory genes have reached phase I and II clinical trials, with promising evidence of target gene down-regulation and therapeutic ecacy in some treated patients (O'Dwyer et al., 1999; Nemunaitis et al., 1999; Waters et al., 2000) . It is possible that HER2/neu-speci®c antisense compounds may eventually play a role in the management of breast cancer patients whose tumors overexpress this oncogene. 
